Purdue announced data from a long-term safety and efficacy study of Hysingla ER (hydrocodone bitartrate extended-release) tablets with abuse-deterrent properties. Study results are being presented at the 34th Annual American Pain Society Scientific Meeting.
The long-term, open-label study with a 76-week maintenance period evaluated the safety and effectiveness and other outcomes of Hysingla ER in 106 opioid-naive and opioid-experienced patients with moderate-to-severe chronic pain. Treatment with Hysingla ER led to improvements in and maintenance of chronic pain relief without the need for dose increase.
The most common treatment-emergent adverse events were constipation, nausea, upper respiratory tract infection, and fatigue. No cases of abuse or diversion of study drug were reported, and no safety concerns were raised from various audiologic, clinical laboratory, and ECG assessments.
Hysingla ER is a Schedule CII opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. It is supplied as 20mg, 30mg, 40mg, 60mg, 80mg, 100mg, 120mg extended-release tablets in 60-count bottles.
For more information call (888) 726-7535 or visit HysinglaER.com.